Business Wire

SES

Share
SES Expands O3b mPOWER Technology Ecosystem with Modem Platform Partnerships

SES today announced Gilat and ST Engineering iDirect as its latest technology partners who will be developing the core infrastructure modem platforms for O3b mPOWER , SES’s ground-breaking non-geostationary-satellite orbit (NGSO) communications system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102006117/en/

Gilat and ST Engineering iDirect were selected based on their next-generation modem technologies. Featuring open architectures with a path to full virtualisation, the modems will interface with SES’s differentiated Adaptive Resource Control (ARC) capability and leverage SES’s use of the Open Networking Automation Platform (ONAP) standard. The combination of this and other technologies will give SES the ability to dynamically control and optimise the entire O3b mPOWER system across space and ground infrastructure, enabling the efficient delivery of low-latency and high-throughput satellite-based data services that can be truly customised to fit specific connectivity requirements on land, at sea or in the air anywhere in the world.

O3b mPOWER is SES’s next-generation medium Earth orbit (MEO) communications system. It is currently under construction and on track for launch in 2021. The high-throughput satellites, as well as automated and intelligence-powered ground infrastructure, will deliver low-latency managed services from hundreds of Mbps up to multiple Gbps.

"We are honoured to have been selected by SES, our long-time strategic partner, to provide our next-generation baseband platform for O3b mPOWER. Gilat's innovative ground segment significantly reduces cost-per-bit, delivers a step-change in modem performance, and further integrates with and optimises SES ground and space service delivery," said Ron Levin Vice President Mobility and Global Accounts at Gilat. "Throughout the last year, we have been working closely with SES to develop the platform for O3b mPOWER with the joint goal of bringing to market unparalleled customer experience in all target verticals.”

“We are at the beginning of a new future for our industry. To be selected for O3b mPOWER is a tremendous validation of ST Engineering iDirect's technology vision and proves that ground infrastructure will play a pivotal role in SES’s ambitious goal to transform satellite service delivery,” said Frederik Simoens, CTO, ST Engineering iDirect. “O3b mPOWER is at the forefront of a significant movement to drive a standards-based, virtualised network approach where ground is in lockstep with space. Through our partnership, we will greatly expand the possibilities for global connectivity.”

“The basis of our O3b mPOWER communications system is defined and advanced by a diverse and robust partner ecosystem. As an industry, we are able to embrace the vision of open networking and seamless satellite services because of like-minded partners such as Gilat and ST Engineering iDirect who understand the step-change in system flexibility and capacity that O3b mPOWER will deliver,” said Stewart Sanders, SES’s Executive Vice President of Technology and O3b mPOWER programme manager. “We have first-hand experience over many years of working with both Gilat and ST Engineering iDirect and have always been impressed with their work as well as what their technologies can provide. Hence, we have full confidence in selecting these two outstanding companies as trusted partners for O3b mPOWER and to deliver a key part of our infrastructure supporting an unparalleled customer experience.”

Focused on making satellites a seamless part of global network solutions, SES has been steadily expanding its O3b mPOWER partner ecosystem. In addition to Gilat and ST Engineering iDirect, SES has also announced O3b mPOWER partnerships with SpaceX for launches, ALCAN, Isotropic Systems and Viasat for customer edge terminals, Amdocs for NFV technology, Kythera Space Solutions for the ARC software, Microsoft for gateways , and IBM and Microsoft for cloud connectivity.

Follow us on:

Social Media
Blog
Media Library

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye